% | $
Quotes you view appear here for quick access.

IntelliPharmaCeutics International Inc. Message Board

  • holywallst holywallst Nov 22, 2013 10:24 PM Flag

    8 drugs in the pipeline is a scary scary thing for me...

    8 drugs in the pipeline??? I would c*** in my pants just thinking about it.

    Just 1 FDA denial for 1 drug on other bio companies has brought the entire stock down to the ground almost to penny levels. Imagine what 8 opportunities of FDA denials can do.

    Scary stuff. I would rather short the strengths.

    Sentiment: Strong Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • murrs700 Nov 23, 2013 11:18 AM Flag

      Lol, imagine what 8 approvals would do. Im guessin you shorted in the 2"s, best of luck covering.

    • company burn rate, with zero revenue is $8M a year. Focalin is approved and other doasges are also approved pending exclusivty from others. In 2 years, generic will capture 75% of market share of this drug with 4 players and 50% reduction in price. If you do the math, that would be about $75M revenue for Par and IPCI and if you assume 15% royalty, it would be about $11M .. now drop it another 30% and you get $8M a year. So, IPCI will be breakeven for the next 10 years (2014 might be lumpy as they have exclusivity, but only 15mg and 30mg)

      Now, talk about Rexista. Targeting a $2.5B market share with IPCI and partner sales expected to be around $500M a year. IPCI will find a partner for this drug and FDA approval makes negotiations from a position of strength. I expect partner to pay up to $150M milestone payments + 20% royalty on sales.

      by the way, Rexista is not trying to solve cancer where you wonder will it work or not. Rexista works.

      So, if I were you, I would buy here or lower if it goes for your retirement.

    • We get it, you don't like this stock or company. Why don't you just go away now?

    • The odds are biased for approval because these drugs already have proven safety and efficacy. They are just making them in extended release formulation. So, your scare tactics won't work here.

    • Or one approval to send it from 1.89 to 6.60. We just witnessed that. Perhaps the next run from mid 3s to $$? Only time will tell. We shall see.

    • Just 1 FDA rejection on 1 drug for other companies has destroyed those bio stocks. That's no bash, that's a fact.

      And you are telling me there was 8 in this pipeline so chances of failure and FDA rejection are mutiplied 8 times??? Is that what you are telling me? And you are overjoyed about that fact as an investor???

      Sentiment: Strong Sell

2.19-0.06(-2.67%)Feb 12 4:00 PMEST